Responses with anti-PD-1/PD-L1 therapy were seen in patients with EGFR- and KRAS-wildtype and EGFR- and KRAS-mutant NSCLC; however, low numbers of enrolled patients in these trials precluded relationship of mutation status with clinical outcomes after anti-PD-1/PD-L1 therapy. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.